Top Markets
#1 Resolv wstUSR Resolv wstUSR +114.62%
#2 Luxxcoin Luxxcoin +45.27%
#3 ResearchCoin ResearchCoin +22.78%
#4 Reactive Network Reactive Network +20.67%
#5 Orderly Network Orderly Network +16.77%
#6 Layer3 Layer3 +13.71%
#7 Bitgert Bitgert +13.08%
#8 Aria.AI Aria.AI +11.86%
#9 Useless Coin Useless Coin +9.66%
#10 Lisk Bridged wstETH (Lisk) Lisk Bridged wstETH (Lisk) +9.53%
Coin of the day
Resolv wstUSR Resolv wstUSR
Innstillinger
Språk
NORSK
Valuta
USD
Tema
CSL Limited CSL Limited

CSL Limited

CSL
Rangering i aksjer #432
CSL Limited researches, develops, manufactures, markets, and distributes... CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Aksjekurs
$99.32
Markedsverdi
$48.20B
Endring (1 dag)
0.98%
Endring (1 år)
-32.14%
Land
AU
Handel CSL Limited (CSL)

Kategori

Healthcare
Antall utestående aksjer for CSL Limited (CSL)
Antall utestående aksjer per December 2025: 483.58M
Ifølge CSL Limited sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 483.58M. Ved slutten av June 2024 hadde selskapet 483.01M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for CSL Limited (CSL) fra 2000 til 2026
Utestående aksjer ved utgangen av hvert år
År Utestående aksjer Endre
2026 (TTM) 483.58M -0.06%
2025 483.88M 0.18%
2024 483.01M 0.17%
2023 482.17M 2.86%
2022 468.76M 3.05%
2021 454.87M 0.23%
2020 453.81M 0.20%
2019 452.92M 0.13%
2018 452.35M -0.65%
2017 455.33M -1.44%
2016 462.00M -2.08%
2015 471.82M -2.48%
2014 483.82M -2.97%
2013 498.61M -3.97%
2012 519.23M -3.94%
2011 540.53M -4.63%
2010 566.78M -4.78%
2009 595.24M 8.21%
2008 550.11M 0.44%
2007 547.71M 0.30%
2006 546.08M -7.12%
2005 587.97M 10.00%
2004 534.52M 11.94%
2003 477.51M 0.53%
2002 474.99M 5.89%
2001 448.57M 12.11%
2000 400.11M 0.00%
Utestående aksjer for lignende selskaper eller konkurrenter
Selskap Utestående aksjer Forskjell Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 4.45B 819.78%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -47.50%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 102.90M -78.72%
US
UCB SA UCB SA
UCB SA
UCB.BR
 190.00M -60.71%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 61.42M -87.30%
NL